Total
0
Shares
MediPharm Labs - Asia Pacific CEO, Warren Everitt - The Market Herald Canada
Asia Pacific CEO, Warren Everitt
Source: South Gippsland Sentinel Times
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MediPharm Labs (LABS) expands its global portfolio in 9 countries including medical and wellness customers for Turnkey Manufacturing and Distribution Solutions
  • MediPharm Labs will provide pre-formulated GMP certified full-spectrum cannabis concentrates that will be distributed to patients 
  • MediPharm Labs is encouraged by the pace of growth in emerging international cannabis markets with large populations
  • Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates
  • MediPharm Labs Corp. (LABS) is up 3.26 per cent and is trading at C$0.48 at 12:37 pm ET

MediPharm Labs Corp (LABS) has signed a new agreement with MT Pharma, based in Malta to supply premium, GMP-certified, finished dose cannabis oil for patients.

MediPharm Labs continues to see significant growth opportunities ahead as numerous pharmaceutical, medical, wellness customers and brands continue to chose MediPharm as their preferred partner for turnkey GMP certified manufacturing and proven global supply chain distribution capabilities.

“Many have chosen to develop products, secure a GMP certified supply chain and open distribution channels through a partnership with MediPharm,” said Keith Strachan, President, and Interim Chief Executive Officer, MediPharm Labs.

“These customers have contracted MediPharm to provide a turnkey solution to enhance their offerings with innovative high-quality wellness products, and future potential registered pharmaceutical drugs containing cannabis, to meet patient and physician demand for personalized therapeutics and medicines,” added Strachan.

Under MedPharm Labs Australia Pty. Ltd.’s two year-agreement, subject to further renewals, with MT Pharma, MediPharm Labs will provide pre-formulated GMP certified full-spectrum cannabis concentrates that will be distributed to patients through pharmacies that will complete final formulation and fill.

MediPharm Labs is encouraged by the pace of growth in emerging international cannabis markets with large populations and strictly defined GMP regulatory frameworks for cannabis, particularly Europe, Latin America, and the United States.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms.

MediPharm Labs Corp. (LABS) is up 3.26 per cent and is trading at C$0.48 at 12:37 pm ET. 

More From The Market Herald
Aleafia Health (TSX:AH) launches cannabis soft chews

" Pure Extracts (CSE:PULL) ships initial order of edible gummies to Alberta

Pure Extracts Technologies (PULL) has shipped its initial order of edible gummies to Alberta Gaming, Liquor & Cannabis (AGLC).
The Hash Corporation (CSE:REZN) completes first commercial batch of rosin

" The Hash Corporation (CSE:REZN) completes first commercial batch of rosin

The Hash Corporation (REZN) has completed its first craft batches of bubble hash and rosin in collaboration with Black Rose Organics Canada.
Nextleaf Solutions (CSE:OILS) awarded U.S. patent for CBG Acetate

" Nextleaf Solutions (CSE:OILS) awarded U.S. patent for CBG Acetate

Nextleaf Solutions (OILS) has been granted a U.S. patent for its novel process of acetylating Cannabigerol (CBG).
EnWave (TSXV:ENW) signs commercial license with Cannaponics PTY Limited

" EnWave (TSXV:ENW) signs another Australian cannabis company

EnWave Corporation (ENW) has granted an Australian cannabis company the right to use EnWave’s patented REV technology for cannabis production.